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Abstract Episodic and recurrent local cutaneous or mucosal
swelling are key features of angioedema. The vasoactive
agents histamine and bradykinin are highly implicated as me-
diators of these swelling attacks. It is challenging to assess the
contribution of bradykinin to the clinical expression of angio-
edema, as accurate biomarkers for the generation of this vaso-
active peptide are still lacking. In this review, we will describe
the mechanisms that are responsible for bradykinin production
in hereditary angioedema (HAE) and the central role that the
coagulation factor XII (FXII) plays in it. Evidently, several
plasma parameters of coagulation change during attacks of
HAE and may prove valuable biomarkers for disease activity.
We propose that these changes are secondary to vascular leak-
age, rather than a direct consequence of FXII activation.
Furthermore, biomarkers for fibrinolytic system activation
(i.e. plasminogen activation) also change during attacks of
HAE. These changes may reflect triggering of the
bradykinin-forming mechanisms by plasmin. Finally, multiple
lines of evidence suggest that neutrophil activation and mast-
cell activation are functionally linked to bradykinin produc-
tion. We put forward the paradigm that FXII functions as a
‘sensor molecule’ to detect conditions that require bradykinin
release via crosstalk with cell-derived enzymes.
Understanding the mechanisms that drive bradykinin genera-
tion may help to identify angioedema patients that have
bradykinin-mediated disease and could benefit from a targeted
treatment.
Keywords Angioedema . HAE . Histamine . Bradykinin .








HK High molecular weight kininogen
NET Neutrophil extracellular trap
PAI Plasminogen activator inhibitor
PPK Plasma prekallikrein
PK Plasma kallikrein
r-tPA Recombinant tissue plasminogen activator
tPA Tissue plasminogen activator
uPA Urokinase plasminogen activator
TF Tissue factor
Introduction
Angioedema is characterized by local, non-itchy, cutaneous or
mucosal edema that lasts for hours up to a few days.
Angioedema is by definition a pathophysiologic process involv-
ing increased permeability of the vascular endothelial lining of
small blood vessels (mostly post-capillary venules). The clinical
picture of angioedema is well-defined, but the underlying mech-
anisms responsible for the swellings are not fully understood.
Two vasoactive agents are implicated in mediating swelling
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attacks in angioedema. The first is histamine, released by mast
cells or basophils. Histamine is the main suspect mediator in
allergic reactions, since angioedema can be seen in anaphylaxis
[1] or as a concurrent symptom of the mast-cell-driven diseases
like chronic spontaneous urticaria [2]. For angioedema with
unknown aetiology (idiopathic angioedema), histamine receptor
antagonists are clinically applied on a trial-and-error basis,
sometimes with higher than recommended doses [2, 3].
Approximately one in six patients with idiopathic angioedema
remains unresponsive to antihistamines [4, 5]. In such cases, the
involvement of other mediators should be considered.
The second suspect mediator of angioedema is bradykinin.
This vasoactive peptide was first identified as a mediator for
angioedema in patients with hereditary angioedema (HAE)
[6–8]. Bradykinin is the end-product of the contact activation
system. This enzymatic cascade circulates in the plasma and
consists of factor XII (FXII), plasma prekallikrein (PPK) and
high molecular weight kininogen (HK). This system is linked
to the intrinsic coagulation system via factor XI (FXI).
Classically, the contact activation system is considered to be
a redundant part of the blood coagulation system. In vitro,
FXII auto-activates when it binds to negatively charged sur-
faces such as glass or kaolin, hence the name ‘contact system’.
Active FXII (FXIIa) activates PPK (Fig. 1). When activated,
plasma kallikrein (PK) liberates bradykinin from HK by
cleavage. At present time, it is unknown how bradykinin is
produced in the human body. Several studies suggested po-
tential natural activators of FXII [9–13], but thus far none of
these have been definitively established to induce activation of
the contact system during angioedema in vivo.
Here, we will discuss the role of bradykinin in angioedema,
the link to the coagulation system and how bradykininmay be
produced in vivo.
Bradykinin-Mediated Angioedema
The available genetic evidence of HAE-related mutations
clearly points towards a central role of the plasma contact
system in this disease. Most HAE patients have SERPING1
gene mutations (encoding for C1-inhibitor (C1-INH) produc-
tion) [14, 15] while a small minority havemutations in the F12
gene, with normal C1-INH activity [16–20].
Hereditary angioedema is hallmarked by recurrent attacks of
angioedema. Attacks can be life-threatening when swelling
compromises the airways, and extremely painful when located
in the intestine [21, 22]. Therapy targeting the contact system
has been successful in HAE, strongly supporting the concept
that angioedema is mediated via bradykinin production
[23–25]. Evidence for bradykinin involvement in angioedema
is not limited to HAE. First, a comparable phenotype can be
observed in patients that have acquired C1-INH deficiency due
to underlying auto-immune or lymphoproliferative disease [26,
27]. Second, anti-hypertensive drugs that inhibit bradykinin
breakdown, such as angiotensin-converting enzyme (ACE),
dipeptidyl peptidase IV (DPPIV) or neprilysin (NEP), can in-
duce angioedema. During clinical trials of NEP inhibitors [28],
up to 2.17 % of patients and 0.2–0.65 % of patients prescribed
ACE inhibitors developed angioedema [29, 30].
Evidently, contact activation is closely linked to the coag-
ulation system [31–33]. Activation of coagulation and fibri-
nolysis during HAE attacks has been repeatedly reported
[34–47]. Yet, HAE patients present with swellings but not
with thrombotic tendency [37]. Combined genetic and clinical
findings suggest that a subset of coagulation factors are ac-
tively involved in angioedema attacks.
Blood Coagulation
Coagulation factors are readily available throughout the blood
circulation to initiate fibrin formation and reinforce platelet
plugs at sites of injury. These interactions are essential to ensure
a properly functioning hemostatic system (Fig. 1). This system
consists of a set of precursor proteins (zymogens) that circulate
in the blood and has to be activated to become biologically
active. The key initiator of the coagulation system, tissue factor
(TF), is normally not present in the circulation. Cells that sur-
round the vessel wall express TF so that only when the endo-
thelial layer is compromisedwill locally active coagulation take
place [48, 49]. After binding to TF, activated factor VII (FVII)
of the extrinsic pathway activates factor X (FX), and to a lesser
extent factor IX (FIX) [50]. Activated FX next triggers the
formation of a small amount of active factor II (thrombin).
Thrombin accelerates coagulation via positive feedback mech-
anisms. Factor VIII (FVIII), activated by thrombin, forms a
complex together with FIX that strongly increases additional
FXa and thrombin generation. Thrombin activates factor V
( FV) that, in a similar manner, contributes to thrombin forma-
tion in complex with FXa. Furthermore, FXI of the intrinsic
pathway is also activated by thrombin [51], and additional FIX
is being amplified by thrombin activation. Ultimately, thrombin
converts fibrinogen into fibrin. Fibrin strands are reinforced
through cross-linking by activated factor XIII (FXIII) (also ac-
tivated by thrombin). The fibrin lattice, together with platelet
aggregates and trapped red blood cells, forms a thrombus to
seal the damaged area and prevent further haemorrhage. The
initiator of this cascade of events, TF, is of vital importance
since TF deficiency is lethal and incompatible with normal
embryonic development or may cause early death in the peri-
natal period [52].
Factor XII as a Coagulation Factor
When blood comes into contact with negatively charged sur-
faces, FXII activates spontaneously. FXIIa subsequently
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activates FXI, thereby providing an alternative trigger for co-
agulation that is independent of TF—the intrinsic pathway.
FXII does not take part in the positive feedback mechanism
of thrombin. As a result of the discovery of this in vitro mech-
anism, FXII is generally regarded as a coagulation factor.
Mysteriously, FXII deficiency is a seemingly asymptomat-
ic condition in both mice and human (Hageman’s disease), as
it is not associated with a bleeding tendency, unlike deficien-
cies of other coagulation factors [53]. The same holds for the
other components of the contact system cascade; their defi-
ciency does not result in bleeding [54]. This makes the rele-
vance of FXII and the contact system for physiological hemo-
stasis debatable. This logic raises a pertinent question: should
FXII be regarded as a coagulation factor, as far as angioedema
is concerned? It has been demonstrated that the bradykinin-
producing contact system machinery can be fully activated in
plasma without evidence of coagulation [10, 11, 55].
This might be explained by the physical properties of
FXII(a): in a sequence of cleavage events, FXIIa is
progressively fragmented. The fragment that remains af-
ter multiple cleavages (βFXIIa or FXIIf) has lost its
potential for coagulation while its bradykinin-forming
potential remains intact.
Factor XII as a Bradykinin-Generating Factor
Although the relevance of FXII for coagulation and hemosta-
sis seems to be limited to in vitro experiments, this is certainly
not the case for bradykinin production. Low levels of
bradykinin are continuously formed and present in the blood-
stream. Murine models of FXII deficiency indicate that the
basal production of bradykinin in plasma is approximately
50 % dependent on FXII [56]. This suggests the presence of
a second pathway generating bradykinin in vivo. Several al-
ternative, FXII-independent routes for initiation of bradykinin
generation have been identified. The endothelial cell-derived
f a c t o r s h e a t s h o c k p ro t e i n 9 0 (HSP9 0 ) a n d
prolylcarboxypeptidase may facilitate FXII-independent
Fig. 1 Overview of coagulation, contact activation and fibrinolysis. The
coagulation cascade is initiated by either tissue factor (TF) or FXIIa.
Positive feedback by thrombin (FIIa) accelerates coagulation. The end-
product of coagulation is fibrin, cross-linked by factor XIII. Fibrin is
degraded by plasmin. During this process, D-dimer, an important clinical
biomarker for thrombosis, is generated. Fibrinolysis is started when tPA
bound to fibrin, or uPA expressed on the endothelium, converts
plasminogen into plasmin. Contact activation starts with the activation
of FXII that will eventually lead to bradykinin release and vascular leak-
age. C1-INH is the most important inhibitor of contact activation and a
weak inhibitor of plasmin. Anti-thrombin (AT) inhibits coagulation and
α2-antiplasmin inhibits plasmin; complexes between enzymes and these
inhibitors can bemeasured in plasma as biomarkers for contact activation,
coagulation and fibrinolysis. PAI-1 inhibits plasminogen activation via
inhibition of tPA and uPA. TAFI modulates plasminogen to prevent acti-
vation. Abbreviations: TF tissue factor, FXIIa activate factor XII, PK
plasma prekallikrein, KK kallikrein, HMWK high molecular weight ki-
ninogen, BK bradykinin, C1-INH C1 inhibitor, AT anti-thrombin, α2AP
α2-anti-plasmin, TAFI thrombin activatable fibrinolysis inhibitor, PAI
plasminogen activator inhibitor, tPA tissue plasminogen activator, uPA
urokinase plasminogen activator
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PPK activation on the endothelial cell surface [57]. Moreover,
bradykinin can be directly released from HK by other en-
zymes than PK; this was recently demonstrated for Mannose
Binding Serine Protease 1 [58]. The relevance of these FXII-
independent pathways of bradykinin generation needs to
be established. It is imaginable that during endothelial
cell activation or damage, small amounts of PPK are
activated by these mechanisms, which boost up FXII
activation as a result.
The clinical importance of FXII for bradykinin generation
was already demonstrated in HAE patients. Genome-wide
screening of a subset of HAE patients with normal C1-INH
level and function (formerly called type III HAE) resulted in
the discovery of disease-related mutations in the F12 gene
(named FXII-HAE). Since then, several mutations in HAE
patients have been described, (mostly) located in the proline-
rich region of FXII (according tomature amino acid sequence:
Thr309Arg, Thr309Lys, Ala324Pro, 72-bp deletion at
c971_1018þ24 and an 18-bp duplication c894_911, and
c1681-1G/A in intron 13) [16–20, 59]. Additionally, isolated
cases of normal C1-INH with FXII mutation have been suc-
cessfully treated with the bradykinin-receptor antagonist—
icatibant.
Plasminogen Activation and Fibrinolysis
After a thrombus has fulfilled its hemostatic function, it
has to be cleared. This natural process is mediated
mainly by the breakdown of fibrin: fibrinolysis
(Fig. 1). Plasmin, the central enzyme of the fibrinolytic
system, cleaves the fibrin lattice into smaller fibrin deg-
radation products (FDPs) including D-dimers, which are
regarded as a valuable biomarker for thrombosis [60].
Plasmin is generated from its zymogenic precursor plas-
minogen by either tissue plasminogen activator (tPA) or
urokinase plasminogen activator (uPA) [61]. Fibrin pro-
vides a platform for its own degradation by binding and
potentiating both tPA and plasminogen. The fibrinolytic
system is amenable to inhibition at several stages:
plasmin is directly inhibited by α2-antiplasmin, while
specific inhibitors of plasminogen activators (PAI-1
and PAI-2) control tPA and uPA [61, 62]. Activation
of plasminogen on the fibrin lattice is indirectly
prevented by thrombin-activatable fibrinolysis inhibitor,
via removal of C-terminal lysines that are needed for
the binding of tPA and plasminogen to f ibrin .
Intriguingly, plasminogen activation on the endothelium
can take place in the absence of fibrin when the uPA
receptor is expressed [63]. This, amongst others, occurs
during tissue injury and hypoxia and makes it attractive
to speculate that plasmin may have additional functions
beyond fibrinolysis.
A Functional Link Between Plasminogen Activation
and Contact System Activation
As formerly discussed, the most important function of FXII
appears to be activation of PPK. Besides that, FXII is also
capable of activation of plasminogen [33, 64, 65]. Compared
to tPA and uPA, FXIIa is a relatively weak plasminogen acti-
vator. However, population studies have proposed that FXIIa
may protect against cardiovascular disease via plasminogen
activation [66, 67]. This may be attributable to additional in-
teractions between the contact system and the fibrinolytic sys-
tem: FXIIa can enzymatically inactivate PAI-1 [68], whereas
PK stimulates uPA activation on the endothelium [65].
Evidence for Plasmin as Natural FXII Activator
There is also evidence that the fibrinolytic system triggers the
activation of the contact system. It has been demonstrated that
plasmin can induce FXII activation in vitro [69]. In line with
this finding, patients with myocardial infarction treated with
therapeutic plasminogen-activating agents, such as streptoki-
nase or recombinant tPA (r-tPA), showed increased plasma
levels of cleaved HK (a surrogate marker for bradykinin re-
lease) [69] and elevated plasma levels of FXIIa [70]. Other
clinical observations also support the importance of plasmin
as a natural FXII activator. Neurologists repeatedly reported
angioedema, which is presumably mediated via bradykinin, as
a side effect of plasminogen activators given to patients with
ischaemic stroke [71–82]. Up to 8 % of stroke patients receiv-
ing r-tPA develop angioedema, often located in the oral cavity
and lingual region and contralateral to the infarction site [83].
Similar observations were made with other thrombolytic
agents [84–86]. A study with 42 post-r-tPA angioedema cases
reported that five patients required emergency intubation or
cricothyroidotomy due to laryngeal swelling, with fatal out-
come in two cases. Notably, concurrent use of ACE inhibitors
is also reported in patients who developed angioedema during
r-tPA treatment [78, 79, 83]. Evidence for plasmin-dependent
bradykinin generation as a cause of angioedema during treat-
ment with fibrinolytic agents is accumulating. However, the
majority of these adverse reactions are still treated as a
histamine-driven hypersensitivity reaction [86]. Future studies
should determine if targeting the contact system is beneficial
for treatment of angioedema as a side effect of fibrinolytic
therapy. Putting these data together makes a strong case for
plasmin-dependent activation of FXII in vivo.
The Involvement of Plasmin in HAE Attacks
We recently investigated three subtypes of FXII-HAE patients
with F12 gene mutations [87] (Unexpectedly, these patients’
plasma did not enhance FXII-dependent coagulation after
contact with a negatively charged compound in vitro (i.e.
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kaolin). This is in good correspondence with the normal
clotting times that were reported in FXII-HAE patients [18].
These patients’ plasma also did not become unusually active
upon cleavage by plasma kallikrein. Detailed biochemical
studies showed that these mutations introduce new cleavage
sites in the FXII molecule. The mutated sites are collectively
sensitive to cleavage by plasmin, resulting in enhanced sus-
ceptibility for activation. Analyses of plasma from two FXII-
HAE patients who carry the F12 mutation T309K showed that
the plasmin-forming potential correlated with disease activity.
These findings underscore the clinical relevance of plasmin as
a FXII activator.
Empiric body of evidence for the importance of plasmin in
the pathology of HAE has been presented in the last four
decades. Anti-fibrinolytic therapy, mainly tranexamic acid,
has been used as prophylactic therapy for HAE attacks since
the 1970s [4, 88, 89]. Tranexamic acid is a lysine derivate
(analogue) that binds to lysine-binding sites of plasminogen
and thereby prevents its binding to fibrin and subsequent ac-
tivation by tPA or uPA [90]. Moreover, HAE patients with
normal C1-INH levels (i.e. FXII-HAE) have decreased levels
of PAI-2 during remission compared to patients with HAE due
to C1-INH deficiency [36]. This suggests that their angioede-
ma episodes might have originated from inadequate inhibition
of plasminogen activation and bradykinin formation down-
stream activated FXII. These findings together point out that
plasmin formation and contact system initiation might be
linked.
Biomarkers of Contact Activation, Fibrinolytic
Activity and Coagulation in Angioedema
Detection of Contact System Activation
As bradykinin was already proven to be the pivotal mediator
of angioedema, biomarkers for its production or predecessors
are highly sought after, as they may help in diagnosis, moni-
toring disease activity and response to treatment. Bradykinin
is only present in the circulation for a few seconds after it is
released from HK, due to rapid degradation by kininases [91]
which complicates its detection. Activation products of con-
tact system activation in plasma are valuable biomarkers as
they may reflect recent bradykinin production. However, due
to pre-analytical in vitro activation, accurate measurements
have proved to be challenging and relatively labour-
intensive (see Farkas et al., Chapter 7 in this issue).
Circulating cleaved HK seems to be among the most suitable
biomarkers for contact activation since cleaved HK levels have
been shown to correlate with attack frequency [92]. Currently,
cleaved HK can be detected by immunoblotting [92]. This as-
say often shows profound cleavage of HK in citrated plasma
from patients with C1-INH deficiency. A diagnostic tool that
could specifically measure cleaved HK, only after it has re-
leased bradykinin, would be a compelling instrument for
HAE diagnosis and follow-up, but is currently lacking.
Biomarkers of Coagulation and Plasminogen Activation
There is a large base of evidence that contact activation during
angioedema attacks is accompanied by changes in the fibrino-
lytic and coagulation systems that could serve as disease bio-
markers [34–47, 93–95]. The understanding that the contact
system and fibrinolytic system are functionally linked sheds a
new light on the repeatedly reported occurrence of increased
levels of complexes of plasmin and its main inhibitor α2-
antiplasmin (PAP) and decreased levels of PAI-1measured dur-
ing HAE attacks [34–36, 39, 40, 43, 44]. Fibrinolytic bio-
markers may also be helpful in identifying bradykinin-mediated
angioedema. The presence of these biomarkers in any patient
that presents with angioedema in the absence of apparent evi-
dence for thromboembolic event should raise the suspicion that
the contact system is involved. Interestingly, parameters of co-
agulation are repeatedly reported to be increased in HAE. D-
dimer levels are elevated during remission periods and mark-
edly increase during attacks [34, 37, 39, 40, 93]. Also, throm-
bin-anti-thrombin complexes and prothrombin fragments F1+
F2 increase during attacks [34, 39, 40, 42, 43, 93].
The Paradox of Fibrinolysis in HAE
Strikingly, HAE is not associated with increased risk of throm-
botic disease. It is therefore hard to imagine that the coagulation
parameters measured reflect intravascular fibrin formation.
Since HAE is associated with extreme vascular leakage, this
may offer an alternative explanation for this phenomenon. We
would like to propose that when plasma coagulation factors
move into the extravascular space, FVIIa may complex with
TF. This can trigger coagulation in the absence of vascular
injury or intravascular thrombi. Evidence for extrinsic pathway
coagulation was demonstrated by a significant increase of
FVIIa during angioedema attacks in 14 patients, by Cugno et
al. [42]. It would be attractive to hypothesize that increased
coagulation parameters in HAE are secondary to massive vas-
cular leakage (Fig. 2). Even though biomarkers for coagulation,
such as D-dimer, will not directly reflect bradykinin produc-
tion, their strong association with HAEmaymake them helpful
as biomarkers for monitoring disease activity.
Future Perspectives in Angioedema—Natural
Contact System Activation and Bradykinin
Production
Efforts to identify the initial spark of contact activation fo-
cused on the presence of in vivo negatively charged
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compounds (i.e. glycosaminoglycans, misfolded protein ag-
gregates, etc.). The discovery that plasmin can enzymatically
activate FXII, in the absence of a surface, provides an alterna-
tive mechanism for this activation process. The importance is
underscored by observations in HAE and patients receiving r-
tPA therapy. Under physiological circumstances, this mecha-
nism may take place at sites of vascular obstruction, or slow
perfusion, where the tissues are endangered by hypoxia.
Alternatively, minor tissue trauma or infection may provide
signals to the vascular endothelium, resulting in local seques-
tration and activation of the contact system. We postulate that
FXII functions as a ‘sensor molecule’ that interacts with the
environment to detect conditions where increased
vasopermeability is required. Excitingly, it is possible that a
variety of enzymes other than plasmin can fulfil a similar role
and contribute to FXII activation.
Neutrophil Activation and Contact System
Activation are Functionally Linked
Recent work shows that HAE attacks are associated with in-
creasing neutrophil counts and neutrophil elastase levels [96].
Neutrophils are important cells for the innate immunity. They
migrate out of the bloodstream within hours after a pathogen is
detected. Migration of neutrophils to sites of inflammation is
orchestrated by several mechanisms, such as chemotaxis by
interleukins and complement factors and interaction of neutro-
phils with endothelial cell receptors [97]. It can be envisioned
that neutrophils interact with the contact system to boost neu-
trophil extravasation by bradykinin-mediated vasodilatation.
First of all, neutrophil elastase, released by active neutrophils,
inactivates C1-INH thereby allowing contact activation to take
place [98]. Second, in vitro studies show that the bradykinin B1
receptor (BKB1R) regulates neutrophil trafficking [99, 100].
Third, both kallikrein and FXIIa can induce neutrophil degran-
ulation [101]. Finally, neutrophil extracellular traps (NETs)
have been shown to activate FXII. NETs exist of DNA, and
the negative charge of DNA is believed to induce auto-
activation of FXII [102]. At the very least, NETs can sequester
FXII and present it for activating cleavage. NETs are a binding
site for antimicrobial proteins such as histones, neutrophil elas-
tase and cathepsins [99]. To what extent the proteins loaded on
NETs contribute to neutrophil-induced FXII activation is not
yet elucidated. The negative charge of NETs, in combination
with potential FXII-activating enzymes, would make neutro-
phils a plausible platform for contact activation. Further re-
search to neutrophil and FXII activation may help understand
its possible relevance for HAE patients.
Mast Cell Activation Is Linked to Bradykinin
Generation
Angioedema as a symptom of anaphylaxis and chronic spon-
taneous urticaria is likely to be mediated by mast cell/basophil
activation.Histamine is the central chemical mediator released
by mast cells, inducing hyperpermeability and vasodilatation,
and is therefore held responsible for the angioedema seen in
allergic responses. Indeed, anti-histamine therapy reduces the
occurrence of angioedema in urticaria patients [2]. It should be
noted that plasma bradykinin levels were not found elevated
in four patients with an acute attack of anti-histamine-sensitive
angioedema [103]. Yet, evidence accumulates that angioede-
ma in allergic reactions is also accompanied by bradykinin
release. FXIIa-C1-INH complexes and kallikrein-C1-INH
complexes were increased up to tenfold, within minutes after
experimental insect stings in six allergic patients who devel-
oped shock or angioedema [1]. In contrast, patients who only
developed urticarial rash in reaction to the venom showed a
non-significant increase in C1-INH complexes. In line with
these results, it was shown that in the patients with angioede-
ma or shock, a third up to half of the total pool of plasma HK
was cleaved within minutes [1]. These results were confirmed
in another study where HK was analysed in patients with an
anaphylactic reaction (mainly induced by food allergens)
[104]. In this study, even patients with a mild reaction (i.e.
gastro-intestinal complaints) showed 60 % cleavage of their
HK pool. Evidence of the clinical relevance of bradykinin
during anaphylaxis with hypotension was further demonstrat-
ed in animal models. Hypotension after IgE-mediated,
antigen-induced anaphylaxis was reduced in FXII-deficient
Fig. 2 Proposed model: increased plasma coagulation parameters
secondary to increased vascular permeability and extravascular
coagulation. Bradykinin binds to its receptors on endothelial cells.
Increased vascular permeability allows extravasation of coagulation
factors. Tissue factor expressed in the extravascular space can initiate
coagulation. In the absence of any injury, the forming fibrin lattice is
continuously degraded by plasmin. Subsequently, D-dimer formed in
the extra vascular space dissipates into the blood stream. Abbreviations:
TF tissue factor, FII factor II, BK bradykinin
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mice compared to wild-type mice [104]. The same protection
toward IgE-mediated hypotension was reported in BKB2R
knockout mice and HK- and PPK-deficient mice [105].
Although direct release of bradykinin from HK by tryptase
could also contribute to these findings, it would be reasonable
to propose that bradykinin production during anaphylaxis is
for a major part FXII-driven.
Moreover, mast cell degranulation may trigger FXII activa-
tion via the release of heparin, which activates FXII in vitro and
induces FXII-dependent hypotension in mice models [10].
Heparin-induced vascular leakage in mice was diminished by
BKB2R antagonist (icatibant) and exaggerated in C1-INH-de-
ficient mice [10]. Heparin is a negatively charged compound,
capable of inducing FXII auto-activation. However, like the
NETs of neutrophils, heparin binds a large variety of proteins
[106]. Contrary to this, a study of 14 HAE patients showed that
tryptase levels do not increase during HAE attacks [107]. It
might be helpful to keep in mind that in HAE patients that also
suffer from allergies, attacks may be aggravated by an allergic
trigger. What do these studies mean for HAE? Angioedema
attacks in HAE are currently not believed to be mast cell-
driven (Ballergic^), and anti-histamine therapy has no effect
on symptoms. So far, there is no solid evidence for an associ-
ation between allergic responses and angioedema attacks.
Additionally, heparin-protein interactions are usually studied
in an isolated in vitro manner. However, the possibility of
protein-protein interactions on heparin extracellular matrix
may be of importance. In the case of FXII, both the net charge
of heparin and nearby proteins might synergistically activate
FXII. Further research into mast cell and FXII interactions may
help to understand the pathological mechanisms behind in vivo
FXII activation and angioedema.
The contribution of bradykinin to angioedema with normal
levels of C1-INH (i.e. chronic spontaneous urticaria with angio-
edema, IH-AAE, InH-AAE, U-HAE, etc.) is still uncertain. It
might be speculated that since FXII activation can result from
mast cell degranulation, bradykinin may also play a supportive
role in forms of angioedema that are currently classified as ‘his-
taminergic’, based on the presence of wheals, pruritus or
(partial) response to anti-histamine therapy. Current studies were
unable so far to demonstrate bradykinin or an increased HK
cleaving in such patients [103, 104, 108]. Considering the strong
evidence of interaction between mast cells and bradykinin pro-
duction, patients with idiopathic angioedema and recurrent
swellings who fail to respond to high-dose anti-histamine treat-
ment might benefit from therapy targeting the contact activation.
Conclusions
& FXII is an important player in bradykinin production dur-
ing HAE attacks. However, it is currently unknown how
FXII activation occurs in vivo.
& Coagulation parameters change during attacks. This is
possibly secondary to vascular leakage, rather than a con-
sequence of FXII activation. However, biomarkers of co-
agulation may reflect disease activity.
& Fibrinolytic parameters change during attacks. These may
reflect a role for plasminogen activation in bradykinin
production (via plasmin).
& Multiple lines of evidence demonstrate that contact system
activation and bradykinin productioncan be triggered by a
variety of cell types, including endothelial cells and mast
cells.
& It is possible that bradykinin plays a role in other forms of
angioedema with normal C1-INH activity, including those
that are currently classified as histaminergic.
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